SEC Info - EyePoint Pharmaceuticals, Inc.

SEC Info℠

Home

Help

Please Sign In

EyePoint Pharmaceuticals, Inc. – ‘8-K’ for 9/15/20

On: Tuesday, 9/15/20, at 4:00pm ET · For: 9/15/20 · Accession #: 1564590-20-43596 · File #: 0-51122

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/15/20  EyePoint Pharmaceuticals, Inc.    8-K:8,9     9/15/20   11:9.2M                                   ActiveDisclosure/FA

Current Report — Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     24K 
 7: R1          Document and Entity Information - Tagging Pending   HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- eypt-8k_20200915_htm                XML     14K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- eypt-20200915_lab                     XML     56K 
 5: EX-101.PRE  XBRL Presentations -- eypt-20200915_pre              XML     34K 
 3: EX-101.SCH  XBRL Schema -- eypt-20200915                         XSD     18K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    20K 
11: ZIP         XBRL Zipped Folder -- 0001564590-20-043596-xbrl      Zip     16K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i 0001314102 0001314102 2020-09-15 2020-09-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): i September 15, 2020

i EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

i Delaware

i 000-51122

i 26-2774444

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

i 480 Pleasant Street

i Watertown, i MA i 02472

(Address of Principal Executive Offices, and Zip Code)

i (617) i 926-5000

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of

each class

Trading

Symbol(s)

Name of each exchange

on which registered

i Common Stock, par value $0.001

i EYPT

i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 15, 2020, EyePoint Pharmaceuticals, Inc. posted an updated corporate presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Corporate Presentation, dated September 15, 2020
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EyePoint Pharmaceuticals, Inc.

Date: September 15, 2020	By:	/s/ *Nancy Lurker*
	Name:	Nancy Lurker
	Title	President and Chief Executive Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	9/15/20	None on these Dates
		List all Filings

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/12/21  EyePoint Pharmaceuticals, Inc.    S-3                    3:260K                                   Donnelley … Solutions/FA
 2/02/21  EyePoint Pharmaceuticals, Inc.    424B5                  1:493K                                   Donnelley … Solutions/FA
 2/01/21  EyePoint Pharmaceuticals, Inc.    424B5                  1:496K                                   Donnelley … Solutions/FA
 1/15/21  EyePoint Pharmaceuticals, Inc.    S-3                    4:662K                                   Donnelley … Solutions/FA
11/06/20  EyePoint Pharmaceuticals, Inc.    S-8        11/06/20    3:88K                                    Donnelley … Solutions/FA

↑Top

Filing Submission 0001564590-20-043596 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)